There is increasing evidence implicating LRRC1 in the progression of certain cancers, including cholangiocarcinoma, hepatocellular carcinoma, and acute myeloid leukemia (AML) [28,29,30]. Here, LRRC1 is linked to cholangiocarcinoma.